Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1

Vall d'Hebron University Hospital (HUVH)

Status and phase: Completed; Phase 2

Conditions: Fanconi Anemia

Treatments: Drug: plerixafor; Drug: filgrastim

Study type: Interventional

Funder types: Other

Identifiers

NCT02931071

2011-006197-88 (EudraCT Number)

FANCOSTEM-1

Details and patient eligibility

About

Fanconi anemia (FA) is a congenital disease characterized by bone marrow failure and increased incidence of malignant tumors. The Project pursue the optimization of the collection of hematopoietic progenitor cells for later use in another clinical trial entitled "Clinical Trial Phase I/II to evaluate the safety and efficacy of the infusion of autologous CD34+ cells mobilized with mozobil and filgrastim, and transduced with a lentiviral vector carrying the FANCA gene (Orphan Drug) for patients with Fanconi Anemia Subtype A ". The objectives of this study are, therefore, to assess the safety and efficacy of CD34+ cells mobilization with mozobil and filgrastim, which is postulated the most efficient for the collection of CD34+ cells from FA patients.

Enrollment: 13 patients

Sex: All

Ages: 2 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female > 1 year
• diagnosed of Fanconi's anemia confirmed by instability chromosomal test with diepoxy-butane or mitomycin C
• At least one of the following parameters must be higher than these values: Hemoglobin:8,0 g/dL; neutrophils: 750/mm3; platelets: 30.000/mm3
• Lansky index> 60%.
• Left ventricular ejection fraction >50%.
• To grant informed consent in agreement with current law norms
• Women in childbearing age must obtain a negative result in the pregnancy test in serum or urine in the visit of selection and accept the use of suitable contraceptive methods since at least 14 days prior to the first dose of mobilizing treatment until the 14 days following the last

Exclusion criteria

• Evidence of myelodysplastic syndromes or leukemia, or cytogenetic abnormalities predicted of these syndromes in bone marrow aspiration. Cytogenetic analyses performed 2 months before starting study are accepted
• Patients with active infection process or any other underlaying severe medical process
• Severe Functional alteration of organs (hepatic, renal, respiratory)(?3), according to National Cancer Institute (NCI CTCAE v3) criteria
• Haematopoietic transplant
• Any disease or concomitant process that is not compatible with the study as per investigator opinion
• Patients not elegible because of an psico-social evaluation
• Patients that received transfusional support during the last 3 months.
• Pregnant or breastfeeding women

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

13 participants in 1 patient group

plerixafor and filgrastim treatment

Experimental group

Description:

to assess the safety and efficacy of CD34+ cells mobilization with plerixafor and filgrastim

Treatment:

Drug: plerixafor

Drug: filgrastim